MILV subsidiary acquires formula to restore proper kidney function

Nature's Bioceuticals, a wholly owned subsidiary of Mistral Ventures Inc. (MILV) announced that it has executed the formal closing documents and acquired the chronic kidney disease (CKD) formula. This formula was developed to restore proper kidney function.

Chronic kidney disease (CKD) is a growing health problem in the United States. A report by the Centers for Disease Control (CDC) determined that 16.8% of all adults above the age of 20 years have chronic kidney disease. The prevalence of chronic kidney disease has increased by 16% from the previous decade. The increasing incidence of diabetes mellitus, hypertension (high blood pressure), obesity, and an aging population have contributed to this increase in kidney disease. Kidney disease raises the risk of early death, heart attack, stroke, and high blood pressure. CKD causes anemia, bone disease and malnutrition and can lead to kidney failure, which requires ongoing dialysis or a kidney transplant to maintain life. According to the National Institute of Health's U.S. Renal Data System, over 100,000 Americans started dialysis in 2005 while a total of over 485,000 received ongoing dialysis treatment or a kidney transplant, at a cost of $32 billion. The NIH estimates that by 2020 nearly 785,000 people will be receiving treatment for kidney failure, costing an estimated $53.6 billion. The healthcare costs for one person needing dialysis are between $150,000 – $200,000 per year, with annual global dialysis costs exceeding $1 trillion this decade.

Robert deZanger, CEO of Natures Bioceuticals reiterates "We are confident that this product will make a meaningful contribution to one of the most overlooked diseases known to man. There are over 26 million Americans with CKD. The problem is most people with CKD aren't even aware they have the disease. Studies show that 4 out of 5 people with advanced CKD (i.e. loss of over 50% of kidney function) do not know they have the disease. Unless tested, diagnosed and dialysis or a transplant is available, many of these people only become unwell after severe kidney failure, when death is imminent. People who have taken our formula have shown substantial increases in kidney function in very short time frames. One positive side effect that has been noted is that the product seems to also shrink enlarged prostrate glands. This could be a second market for the product.  We now intend to initiate the filing of the patent(s) and also make arrangements to begin clinical trials to document the amazing results obtained to this point. The revenues this product could produce for the company should be substantial. Capturing a very small percentage of the market could produce tens of millions of dollars for the company."